TP53 and colorectal carcinoma: To evaluate the influence of age on treatment outcomes in patients with TP53-mutated CRC receiving FOLFOX chemotherapy, we queried AI-HOPE-TP53 to compare survival between early-onset (<50 years) and late-onset (≥50 years) patient groups.